John Nuss Reduces Stake in Ventyx Biosciences by Selling Shares

On Thursday, December 19th, John Nuss, an insider at Ventyx Biosciences, Inc. (NASDAQ:VTYX), sold 13,161 shares of the company's stock. The shares were sold at an average price of $2.26, resulting in a total transaction value of $29,743.86. Following this transaction, Nuss now directly holds 485,701 shares of Ventyx, which are worth approximately $1,097,684.26. This sale accounts for a 2.64% reduction in his ownership of the company's stock. The details of this transaction were outlined in a filing with the SEC that can be accessed for more information.

Ventyx Biosciences Stock Performance

During midday trading on Thursday, the stock price for Ventyx Biosciences fell slightly by $0.02, bringing its price to $2.28. The trading volume for the day reached 1,760,269 shares, which is lower than its average volume of 2,039,973 shares. Ventyx has a market capitalization of $161.22 million, a PE ratio of -0.97, and a beta of 0.48. The company’s stock price has ranged from a 52-week low of $1.67 to a high of $11.48. Over the past 50 days, the simple moving average has been $2.30, and over the last 200 days, it stands at $2.40.

Institutional Trading of Ventyx Biosciences

Several institutional investors have recently adjusted their positions in Ventyx Biosciences. For instance, Deerfield Management Company L.P. Series C increased its holdings by 64.6% in the second quarter, now owning 5,829,570 shares valued at $13,466,000 after acquiring an additional 2,287,570 shares. Similarly, Sio Capital Management LLC raised its stake by 153.2% during the third quarter, now holding 1,971,948 shares valued at $4,299,000 after an additional purchase of 1,193,024 shares. Vestal Point Capital LP also increased its holdings by 31.2%, obtaining 1,725,000 shares worth $3,760,000 after buying an extra 410,000 shares. Additionally, Acadian Asset Management LLC and XTX Topco Ltd made new investments in the company, further indicating strong institutional interest. In total, institutional investors own 97.88% of Ventyx's stock.

Wall Street Analyst Opinions

Research analysts have issued various ratings for Ventyx Biosciences. On November 11th, HC Wainwright maintained a "neutral" rating with a target price of $6.00. Similarly, Oppenheimer reaffirmed an "outperform" rating but lowered its target price from $10.00 to $9.00 on November 8th. While one analyst has given the stock a hold rating, four others have assigned buy ratings. Currently, the consensus rating for VTYX is classified as "Moderate Buy" with a consensus target price of $10.00, according to data from MarketBeat.com.

Company Overview

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule candidates for treating inflammatory diseases. The company’s lead product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor intended for the treatment of conditions such as psoriasis, psoriatic arthritis, and Crohn's disease.

Insider, Shares, Stock